Calidi Biotherapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Calidi Biotherapeutics, Inc. (CLDI) on October 27, 2023, reporting events that occurred on October 23, 2023. The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the departure of senior financial leadership:
- On October 23, 2023, Mr. Tony Kalajian resigned from all positions within the company.
- Mr. Kalajian held the roles of Chief Accounting Officer and interim Chief Financial Officer.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the operational impact of the executive departure.
Investor Verification Checklist
- Confirm the appointment of a new Chief Financial Officer and Chief Accounting Officer to replace Mr. Kalajian.
- Review subsequent filings for any impact on the company's financial reporting timeline or internal controls.
- Verify if the resignation was voluntary or related to undisclosed financial or operational issues.